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specific role of ephrins in bone biol-
ogy. For example, how is expres-
sion of ephrinB2 and EphB4 regu-
lated? Is their expression regulated 
by systemic factors or local factors 
that modulate bone remodeling? 
What is their relationship to com-
mon signaling pathways and other 
important genes involved in osteo-
clast and osteoblast differentiation? 
What is their relationship to the other 
molecular mechanisms proposed for 
coupling, including growth factors, 
and are these mechanisms mutually 
exclusive? Is this a common path-
way utilized by all regulators of bone 
remodeling? Do cancer cells use 
similar bidirectional mechanisms to 
survive, proliferate, and/or use these 
mechanisms to cause the aberrations 
in osteoclast/osteoblast coupling 
that are characteristic of osteolytic 
and osteoblastic bone metastasis? 
The results of this provocative study 
have certainly provided the foun-
dation for many new studies in this 
complex field.
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Integrins modulate signaling by growth factor receptors, but their role during tumorigenesis 
is not clear. Guo et al. (2006) now demonstrate that α6β4 integrin cooperates with ErbB2 
in the formation of mammary tumors and discover distinct pathways that regulate cellular 
proliferation and adhesion downstream of the ErbB2-integrin complex.Integrins are heterodimeric cell 
surface receptors used by cells to 
interact with the extracellular matrix 
(ECM). In addition to performing a 
structural role, integrins are major 
sites of signal initiation and modu-
lation. In particular, integrins and 
receptor tyrosine kinases (RTKs) 
form a cooperative signaling net-
work to regulate various biological 
processes (Hynes, 2002; Miranti and 
Brugge, 2002). For instance, integrin 
adhesion promotes activation of sev-
eral RTKs, including the epidermal 
growth factor receptor (EGFR). Con-versely, RTKs affect cell adhesion, 
spreading, and migration by regulat-
ing integrin localization and activa-
tion. Cooperative signaling between 
RTKs and integrins may also have 
a role in cancer. Even though aber-
rant activation of RTKs and changes 
in integrin expression are involved in 
epithelial malignancies (carcinoma), 
it remains unclear how cooperation 
between integrins and RTKs regu-
lates the initiation of tumor formation 
and progression to carcinoma.
In this issue of Cell, Guo et al. 
(2006) establish that α6β4 integrin, Cell 126, Awhich binds to laminin in the ECM, is 
required for mammary tumorigenesis 
induced by expression of ErbB2, a 
member of the EGFR family of RTKs. 
ErbB2 is a dominant oncogene in 
breast cancer, and it is amplified in 
25%–30% of human breast cancers. 
Amplification of ErbB2 correlates with 
poor clinical prognosis in patients 
whose cancer has progressed to the 
lymph nodes. ErbB2 is also the tar-
get of the drug Herceptin (Citri and 
Yarden, 2006). Guo and colleagues 
exploited two mouse models, one 
that has a targeted deletion of the ugust 11, 2006 ©2006 Elsevier Inc. 443
signaling domain in the cytoplasmic 
portion of the β4 integrin subunit 
and another that expresses a mutant 
version of Neu (the rat homolog of 
human ErbB2). In the absence of β4 
integrin’s signaling domain, initiation 
and metastatic progression of mam-
mary tumors that are induced by 
ErbB2 are significantly delayed, sug-
gesting that α6β4 integrin acts as a 
cooperating oncogene. This notion 
is consistent with previous studies 
using other mouse model systems. 
figure 1. signaling by the erbB2-α6β4 
Integrin complex
ErbB2 induces transformation of the polarized 
mammary epithelia by signaling through both 
α6β4 integrin-independent and -dependent 
pathways. ErbB2 regulates phosphoryla-
tion of the signaling domain of β4 integrin 
by promoting formation of a multimeric com-
plex that includes ErbB2, the tyrosine kinase 
Src, and α6β4 integrin (Guo et al., 2006). Src 
phosphorylates ErbB2 in the P loop of the 
kinase domain, which enhances the kinase 
activity of ErbB2. Cooperative signaling by 
ErbB2 and α6β4 integrins results in activation 
of c-Jun (via c-Jun N-terminal kinase, JNK) 
and STAT3, transcription factors that regulate 
oncogenesis. Activation of the c-Jun pathway 
is required for the changes in proliferation in-
duced by ErbB2, whereas activation of STAT3 
is required for ErbB2-induced disruption of 
tight junctions. In addition to α6β4-depend-
ent pathways, ErbB2 may use the Ras/MAPK 
pathway to stimulate proliferation. It is not 
known whether ErbB2 uses α6β4 integrin-in-
dependent pathways to disrupt tight junctions 
and epithelial organization.444 Cell 126, August 11, 2006 ©2006 ElsFor instance, in a model of human 
epidermal neoplasia induced by 
Ras-NF-κB, primary human keratino-
cytes from patients with mutations in 
β4 integrin fail to form tumors when 
transplanted into nude mice (Dajee et 
al., 2003). Also, α6β4 integrin coop-
erates with chemical carcinogens 
to induce invasive carcinoma when 
overexpressed in the suprabasal 
layer of mouse epidermis (Owens et 
al., 2003). In addition to studies using 
α6β4, β1 integrin is required for initia-
tion and progression of mouse mam-
mary tumors induced by polyoma 
virus middle T antigen (White et al., 
2004). Thus, integrins can cooperate 
with diverse oncogenic signals.
The study reported by Guo et al. 
provides critical insight into the mech-
anism by which integrins cooperate 
with RTKs to cause transformation. 
ErbB2 and β4 integrin synergistically 
activate each other by coopting the 
cytoplasmic tyrosine kinase c-Src 
(Figure 1). ErbB2 induces Src-medi-
ated phosphorylation of the signaling 
domain of β4 integrin by promoting 
formation of a multimeric complex, 
ErbB2-Src-α6β4 integrin. Src in turn 
phosphorylates ErbB2 in the P loop of 
the kinase domain, which enhances 
the kinase activity of ErbB2. These 
observations are consistent with pre-
vious studies that demonstrated a 
role for Src in the activation of EGFR 
that is induced by β1 integrin (Miranti 
and Brugge, 2002). The importance 
of the β1 integrin-EGFR interaction 
in mammary epithelia was revealed 
by another study using three-dimen-
sional (3D) culture models of cancer 
(Wang et al., 1998). In a tumorigenic 
human mammary epithelial cell line 
that expresses high levels of EGFR 
and β1 integrin, downregulation of 
either β1 integrin or inhibition of 
EGFR results in downregulation of 
both β1 integrin and EGFR. This 
downregulation results in a reversion 
of the transformed phenotype, sug-
gesting that the integrin-RTK inter-
action is required for maintaining a 
transformed state and that integrins 
may function to amplify oncogenic 
signaling from RTKs. Although sev-
eral studies have demonstrated that 
integrin expression is misregulated in evier Inc.human cancers, the prognostic sig-
nificance of integrin expression is not 
well understood. A comprehensive 
analysis of changes in coexpression 
of specific integrins and RTKs during 
human cancer progression may be of 
significant prognostic value.
Initiation and progression of epi-
thelial malignancies in vivo are char-
acterized not only by changes in pro-
liferation rates but also by changes 
in epithelial organization and cell 
architecture. Changes in cell-cell and 
cell-matrix adhesions are the primary 
regulators of epithelial organization in 
vivo. Oncogenes, such as ErbB2, are 
known to disrupt epithelial organiza-
tion by promoting cell proliferation 
and disruption of tight junctions, a 
cell-cell junctional complex located 
at the apex of polarized epithelial 
cells (Muthuswamy et al., 2001). The 
study by Guo and colleagues sheds 
light on how oncogenes regulate 
epithelial architecture and prolifera-
tion. The cooperative signaling by 
ErbB2 and α6β4 integrins results in 
activation of two downstream path-
ways, c-Jun and STAT3, which are 
transcription factors that regulate 
oncogenesis. The authors demon-
strate that activation of the c-Jun 
pathway is required for the changes 
in proliferation that are induced by 
ErbB2, whereas activation of STAT3 
is required for ErbB2-induced disrup-
tion of tight junctions. A recent study 
also reported identification of distinct 
pathways that control cell polarity and 
proliferation using a 3D cell culture 
model. Inhibition of the PI3K pathway 
was sufficient to revert a malignant 
phenotype in human breast epithe-
lial cells. Among the effectors of the 
PI3K signaling, Akt was required for 
cell proliferation, whereas the GTP 
binding protein Rac1 was required 
for changes in basal polarity of epi-
thelial cells (Liu et al., 2004). Interest-
ingly, Rac1 can interact with STAT3, 
and EGF-induced activation of STAT3 
requires Rac1 (Simon et al., 2000). 
Together, these results raise the pos-
sibility that deregulation of cell archi-
tecture and cell proliferation may be 
under distinct regulatory control dur-
ing the initiation and progression of 
carcinoma (Figure 1).
It is highly likely that there are 
integrin-dependent and -independ-
ent mechanisms that control trans-
formation induced by oncogenes. 
Inhibition of signaling by β4 integrin 
significantly delayed the mammary 
tumorigenesis induced by ErbB2, 
but did not block it. Although the 
activation of Ras/MAPK mediated by 
ErbB2 could account for the prolif-
eration observed in tumors formed in 
the absence of the β4 integrin signal-
ing domain, it is not known whether 
there are β4-independent mecha-
nisms that mediate ErbB2-induced 
disruption of tight junctions and epi-
thelial organization. Further investi-
gations are needed to answer ques-
tions such as: what are the pathways 
used by oncogenes to disrupt cell 
polarity? Are these pathways selec-
tive for deregulation of cell architec-
ture (Figure 1)?
Such questions lead us to a 
hypothesis. Pathways that deregu-
late cell organization and disrupt cell 
polarity are promising targets for Canine transmissible venereal tumor 
(CTVT, also called Sticker’s sarcoma) 
is a contagious venereal tumor found 
in the domestic dog (Canis familiaris) 
and potentially in other social canids, 
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In this issue of Cell, Murgia et
missible venereal tumor is the
findings have implications for
and transmissible cancer and
animal medicine.cancer therapeutics. Unlike cell pro-
liferation, disruption of cell polarity 
and organization is never observed 
under normal physiological condi-
tions in adult tissue and is unique to 
disease states such as cancer and 
inflammation. If oncogenes disrupt 
epithelial cell polarity using path-
ways that are distinct from those 
involved in the control of prolifera-
tion, further understanding of how 
oncogenes disrupt cell polarity and 
organization can lead to identifica-
tion of new targets for therapeutic 
intervention. Such targets may have 
limited effects on normal cells and 
hence have minimal general toxicity. 
Thus, a comprehensive understand-
ing of the molecular mechanisms 
by which oncogenes disrupt polar-
ity and epithelial organization may 
open doors for a new class of drug 
targets.
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the contagious agent of this disease. 
In this issue of Cell, Murgia and col-
leagues (2006) address the key issue 
of whether CTVT indeed represents 
a “contagious cancer.”
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